Paper · 30397178
Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2.
Chen X and 12 others. Clin Cancer Res, 2019. Cited by 187 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. Papers, record 30397178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30397178
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Enhancer of Zeste Homolog 2 Protein | Major topic |
| Heterogeneous-Nuclear Ribonucleoprotein K | Major topic |
| RNA, Long Noncoding | Major topic |
| SOXB1 Transcription Factors | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Animals | |
| Carcinogenesis | |
| Cell Line, Tumor | |
| Cell Self Renewal | |
| Drug Resistance, Neoplasm | |
| Epigenesis, Genetic | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Gene Silencing | |
| Heterografts | |
| Humans | |
| Male | |
| Mice | |
| Neoplasm Recurrence, Local | |
| Neoplastic Stem Cells | |
| Signal Transduction | |
| Transcriptome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,941,789 | pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941789 | PubMed |
| 42,644,086 | Field cancerization in urothelial carcinoma: molecular alterations and clinical implications. | J Cancer | 2026 | https://conductscience.org/library/papers/42644086 | PubMed |
| 42,410,458 | Role of microRNAs in cisplatin response of cancer stem cells. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/42410458 | PubMed |
| 42,292,383 | From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292383 | PubMed |
| 41,822,755 | Long noncoding RNAs in tumor stemness: emerging mechanisms and therapeutic opportunities. | Front Genet | 2026 | https://conductscience.org/library/papers/41822755 | PubMed |
| 41,716,844 | Harnessing Ribonucleoprotein Granule Biology for Cancer Therapy: The Central Role of Protein Modifications. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/41716844 | PubMed |
| 41,230,155 | Identification of molecular subtypes and prognostic risk model of glucocorticoid-related lncRNAs in bladder cancer to evaluate prognosis and immunological characteristics. | Transl Androl Urol | 2025 | https://conductscience.org/library/papers/41230155 | PubMed |
| 41,076,461 | Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade. | Oncogene | 2025 | https://conductscience.org/library/papers/41076461 | PubMed |
| 40,999,456 | Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40999456 | PubMed |
| 40,968,608 | Long Noncoding RNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability. | Cancer Res Treat | 2026 | https://conductscience.org/library/papers/40968608 | PubMed |
1 to 10 of 139
See all 139 cited byGenes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EZH2 | 2,146 | PubTator's text mining | https://conductscience.org/library/genes/2146 | NCBI Gene |
| HNRNPK | 3,190 | PubTator's text mining | https://conductscience.org/library/genes/3190 | NCBI Gene |
| LNC-LBCS | 100,506,885 | PubTator's text mining | https://conductscience.org/library/genes/100506885 | NCBI Gene |
| SOX2 | 6,657 | PubTator's text mining | https://conductscience.org/library/genes/6657 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30397178
GET https://conductscience.org/api/papers/v1/30397178/cited_by?page=2